Tag: BioPharma

Caris Life Sciences Appoints Brian Lamon, Ph.D., as Chief Business Officer, Head of BioPharma Business Development

IRVING, Texas, Oct. 6, 2020 /PRNewswire/ — Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Brian Lamon, Ph.D., has been appointed Chief Business Officer, Head of BioPharma Business Development.

In this role, Lamon will be responsible for developing the partnering and business development strategy for the company and translating that strategy into actionable and achievable goals for the broader Caris organization.

“We are very excited to welcome Brian to Caris,” said Brian J. Brille, Vice Chairman of Caris Life Sciences. “His expertise in oncology clinical development, business development, translational medicine and medical affairs, and track record of maximizing value from external relationships will further advance our business development strategies to position the company for continued growth.”

Lamon brings over 15 years of experience from large pharma and academia to Caris. He previously worked for Bristol Myers

Read More

CMAB Biopharma and Laekna Therapeutics Enter Strategic Agreement for LAE005 Global Development and Commercialization Partnership

SUZHOU, China, Sept. 10, 2020 /PRNewswire/ — CMAB Biopharma (Suzhou) Inc. (“CMAB”), and Laekna Therapeutics Shanghai Co., Ltd. (“Laekna Therapeutics”), today announced a strategic collaboration agreement in Suzhou BioBAY for speedup of Immune Checkpoint Inhibitor (ICI) drug candidate to the clinical trial and future commercialization.

According to the agreement, CMAB will provide a full spectrum of CMC services based on the recognized global quality standards for Laekna Therapeutics’ anti-PD-L1 antibody (LAE005). Services to be provided by CMAB include technology transfer, process development, GMP clinical drug substance and drug product manufacturing to support IND filing in China and in the US. These services will facilitate the global development and future commercialization of LAE005.

Laekna Therapeutics is a biotechnology innovation company focusing on the research and development of new generation of small molecules for target therapy and antibodies in the field of oncology and liver diseases. In February 2020, Laekna

Read More

PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital

The MarketWatch News Department was not involved in the creation of this content.


INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire via COMTEX/ —
INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ — PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively “Noden”) to Stanley Capital.  The total value of the transaction will result in payments to PDL of up to $52.83 million in cash, $4.58 million greater than previously announced.

“After running an extensive process, we are excited about closing this transaction with Stanley Capital,” commented PDL’s President and CEO Dominique Monnet.  “It represents the completion of a key divestiture for PDL and an exciting opportunity for the Noden team.”

Payments to PDL, in connection with the closing of the transaction, are $12.72 million.  The agreement provides for an additional $33 million

Read More